Hybridon preclinical data

The Worcester, Mass., company published in vivo results with its second-generation antisense oligonucleotides, showing greater stability over phosphorothioate oligonucleotides.

As reported in Biochemical Pharmacology, a hybrid oligonucleotide targeted at the gag gene of HIV-1, given intravenously in rats, persisted unchanged in the circulation for longer than the first-generation, phosphorothioate compound. ...